| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d21cbff64022f95c237c0bd3ec8656ca
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d1c4f631a13c9397c42c615e58e47309
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_47f4f6ca0934873a78591a7f220c2312
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_15133508c5221f057d861b696bc0204f |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2320-34
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-321
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-332
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-346
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-315
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-3521
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-533 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-113
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-713
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-1709 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-713
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-11
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-113 |
| filingDate |
2011-02-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2017-02-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_032efb9771432260c2676de29221fdfe
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_00c8771257b571c7e0e041deb917604d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ddbcb7ea555993ec816f68fc6c19742f |
| publicationDate |
2017-02-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-9574191-B2 |
| titleOfInvention |
Selective inhibition of polyglutamine protein expression |
| abstract |
The present invention relates to the selective inhibition of protein expression of CAG repeat-related disease proteins such as Huntingtin Disease Protein and Ataxin-3 using double-stranded RNAs and nucleic acid analogs. Chemically-modified RNAs having at least one mismatch as compared to the target CAG repeat sequence are specifically contemplated. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11434488-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11583548-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11542501-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10533175-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11293025-B2 |
| priorityDate |
2010-02-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |